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Breast cancer is the female malignant neoplasia with the highest incidence in the industrialized
world. Although early diagnosis has contributed to therapeutic success, breast cancer remains
a major health issue. In the last few year the hormone therapy for estrogen-dependent breast
cancer has evolved achieving signiﬁcant clinical results; at the same time, it has enabled us to
better deﬁne the role of estrogens in the etiopathogenesis of this tumour. Weight increase and
obesity have been identiﬁed as the most important risk and prognostic factors for breast cancer
in postmenopausal women. Several hypotheses have been proposed to explain the association
of obesity with postmenopausal breast cancer. Speciﬁc obesity-associated factors, including
leptin, insulin and inﬂammatory mediators, seem to inﬂuence breast cancer growth and prognosis
independently of estrogens and at least in part by interacting with estrogen signalling at a cellular
level. Therefore, a careful assessment of the nutritional status and body composition is paramount
for a proper therapeutic approach for postmenopausal breast carcinoma. The use of antidiabetic
and anti-inﬂammatory drugs associated with conventional hormone therapies and dietary/physical
interventions could offer a new therapeutic approach for breast carcinoma that develops in the
context of adiposity.
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1. INTRODUCTION
Breast cancer is the most commonly occurring female cancer in the industrialized world. Although early
diagnosis has contributed to therapeutic success, breast cancer remains a major health issue.
About 60% of breast carcinomas are hormone dependent. The hormonal changes in postmenopause,
ascribable to a speciﬁc physical and metabolic remodelling, not only represent a greater risk for breast
cancer, but also are to be considered indispensable for a more effective therapy [1]. Weight increase
and obesity, subsequent to the menopause, have been identiﬁed as the most important risk and negative
prognostic factors for breast cancer in postmenopausal women (Figure 1). Several studies pointed out that
obesewomenexhibitatdiagnosisanincreaseinlymph-nodesinvolvementandahigherpropensitytodistant
metastases [2, 3].
According to this evidence, several hypotheses have been proposed to explain the association of
obesity with postmenopausal breast cancer. The main one is that circulating estrogens from peripheral
aromatization of androgens are higher in obese than in slim postmenopausal women. A second hypothesis
is that obesity, being associated with metabolic syndrome, results in increased circulating levels of insulin
and insulin-like growth factor (IGF), which, by acting as mitogens for epithelial breast cells, stimulate
their growth and neoplastic degeneration. A third hypothesis suggests that adipocytes and their autocrine,
paracrine, and endocrine actions are at the centre of such an etiopathogenetic mechanism (1). Adipocytes,
until recently considered solely as an energy storage depot, are actually recognized as active endocrine
cells producing hormones, growth factors, and cytokines. Indeed, the most likely hypothesis is that all these
mechanisms may combine to explain the association which links together menopause, the subsequent body
weight increase, and hormone-dependent breast cancer.
2. ADIPOSITY, ESTROGENS, AND BREAST CANCER
The most convincing, but indirect, evidence for a role of estrogen associated to obesity in postmenopausal
breast cancer is that circulating levels of estrogens are strongly and linearly related to adiposity [4].
Endogenous estrogens biosynthesis after menopause is catalyzed almost exclusively by the aromatase
enzyme in the adipose tissue. Beside the increased adipose mass, also fat distribution has been correlated
with breast cancer risk and outcome: increased breast cancer risk and mortality have been associated with
upper body obesity as deﬁned by the waist-to-hip ratio, or suprailiac-to-thigh ratio [5].
Moreover, a central role is played by the adipose tissue that sustains and surrounds the breast
glandular tissue and includes a mix of mature adipocytes, undifferentiated ﬁbroblasts, and macrophages.
Changes in ﬁbroblasts distribution may regulate the local synthesis of estrogen, thus inﬂuencing the breast
tumor development. It is important to bear in mind that the ﬁbroblasts, as for quantity, tallies with that of
adipocytes and that both components inﬂuence each other in their peculiar functional capacity. In fact, there
are adipose tissue speciﬁc promoters of stromal cells aromatase, such as the promoter I.4, which, in turn,
are regulated by macrophagic cytokines and glucocorticoids [6]. Furthermore, it seems that the increased
aromatase expression in the adipose tissue of breast bearing carcinoma derives also from the activation of
promoters II and l.3, which are regulated by unknown factors probably released by malignant epithelial
cells: among these prostaglandin, (PG) E2 seems to be a likely candidate [7]. Therefore, the histological
composition of breast tissue may favour the estrogen-dependent growth and progression of breast cancer
cells in a paracrine manner, in which the steroid spreads from its site of synthesis to interact with the ERs on
nearby cancer cells. Moreover, some breast cancers have themselves aromatase activity, and in the presence
of ER+, breast cancer cells are able to stimulate tumour growth by an autocrine mechanism [8].
3. WEIGHT GAIN, INSULIN-RESISTANCE, AND BREAST CANCER RISK
Body mass index (BMI) increase in postmenopausal women is associated not only with hyperestrogenism,
but also with hyperinsulinemia and insulin-resistant type-2 diabetes which, in turn, are associated with a




















FIGURE 1: Different mechanisms of estrogen dependence for hormone-related breast cancer in pre- and
postmenopausal women. In premenopausal women, the main site of synthesis of estrogen is the ovary.
In postmenopausal women, adipose tissue is the main source of the circulating estrogens. Adipose tissue
produces the enzymes aromatase; therefore, in obese women, there is an increased conversion of the
androgens androstenedione and testosterone into the estrogens: oestrone and oestradiol, respectively,
by aromatase. Moreover, obesity, being associated with metabolic syndrome, results in increasingly
circulating levels of insulin and insulin-like growth factor, which, by acting as mitogens for epithelial breast
cells, stimulate their neoplastic degeneration. Moreover, adipocytes produce several “adipokines” such
as leptin and inﬂammatory cytokines which can inﬂuence aromatase activity and estrogen-dependent
cell proliferation. IGF, insulin growth factor; IL, interleukin; TNF-α, tumour necrosis factor-α; Lp, leptin; E,
estradiol; A, aromatase.
slight increase in postmenopausal breast cancer risk [9]. In particular, the increase of visceral adipose tissue
hasbeenassociatedwithhyperinsulinemia,insulin-resistance,anddyslipidemia.Therefore,theinvolvement
of adipose tissue in the pathogenesis of breast cancer is consistent with the identiﬁcation of type-2 diabetes
and metabolic syndrome as risk factors for this tumour. In clinically manifested type 2 diabetes and
metabolic syndrome, tissues are not able to absorb, store, and metabolize glucose efﬁciently. Therefore,
to prevent elevated glucose concentrations in the blood, the pancreas secrete increasing amounts of insulin
in both the fed and fasted states. Hyperinsulinemia, even in the absence of diabetic symptoms, have been
associated with an increase in breast cancer risk. Indeed, insulin exerts a direct mitogenic effect on breast
cancer cells, which is limited to ER+ cancer cell lines. Moreover, insulin has a synergistic activity with
estrogens in regulating c-Myc and cyclin D1 to promote cell-cycle progression [10].
Hyperinsulinemia can also affect indirectly tumorigenesis by contributing to the synthesis and
activity of insulin-growth factor (IGF)-I and II. IGFs can act in an endocrine, paracrine, or autocrine fashion
to regulate cell growth, survival, and differentiation and can synergize with other growth factors to enhance
their mitogenic effect [11]. Analysis of genetic polymorphism showed a signiﬁcant correlation between the
expression of speciﬁc insulin-related genes and increased risk of breast cancer in postmenopausal women
exposed to estrogens. Approximately one half of primary breast cancers overexpresses the IGF-I receptor
(IGF-IR), suggesting that these carcinomas have enhanced responses to the mitogenic and antiapoptotic
effects of IGF-I [12]. Conversely, the inactivation of IGF-IR results in reduced mammary tumor growth
and metastasis in vivo [13]. Binding of IGF-I to the speciﬁc receptor leads to the activation of various
intracellular pathways, including phosphatidylinositol 3-kinase (PI 3-kinase) and mitogen-activated protein
kinase (MAPK) signalling cascade. Both the PI 3-kinase and MAPK pathways are important for IGF-I-
stimulated proliferation of MCF-7 human breast cancer cells and their inhibition abrogate IGFs’ mitogenic
effects [11]. Additionally, the insulin-IGF-I pathway interacts with estrogens to synergistically induce the
mitogenic response in breast epithelial cells. The estradiol in the presence of IGF-I is able to induce the
transcriptional activation of ER to levels higher than observed with the ligand alone, while loss of ER leads
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to a decrease in IGF-I signalling and mitogenic activity [14]. Given that obese postmenopausal women
have more estrogens, IGF-I, and insulin than slim women, it is logical to conclude that the above-described
crosstalkbetweentheIGFpathwaysandestrogen-mediatedsignallingmayfavouranincreasedriskofbreast
cancer to a greater extent in obese postmenopausal women.
Moreover, increased circulating concentrations of insulin and IGF-I cause a reduction in blood
levels of sex hormone-binding globulin (SHBG) with a consequent elevation in the bioavailable fraction
of circulating estradiol [15]. Accordingly, in postmenopausal women, blood levels of SHBG were inversely
correlated with breast cancer risk [16]. Additionally, SHBG may act directly on breast cancer cells to
inhibit estradiol-induced proliferation [17]. Thus, SHBG appears to be a regulator of estradiol action in
breast cancer cells, acting as an antiproliferative factor, loss of which in obese women could contribute to
tumorigenesis.
4. ADIPOKINES AND BREAST CANCER
It has been clearly shown that the adipose tissue is a complex and metabolically active endocrine organ.
Besides the storage and energy regulation function, the adipose tissue is equipped with the metabolic
machinery that enables its communication with distant organs, including the central nervous system
(CNS). Although the adipocytes synthesize and secrete several hormones, such as leptin and adiponectin,
many proteins are produced by the nonadipocyte fraction of the adipose tissue, that is, ﬁbroblasts and
macrophages that inﬁltrate the adipose cell mass: all these factors are known as “adipokines” [18]. Indeed,
adipokines including leptin, tumor necrosis factor-(TNF-)α, interleukin-6 (IL-6), and hepatocyte growth
factors (HGFs), apart from exerting their speciﬁc local biological effects, circulate in the plasma at
concentrations positively correlated with BMI; one exception is adiponectin, which is inversely correlated
with BMI [8].
Several in vitro and in vivo studies demonstrated that adipocytes could directly inﬂuence breast
tumour growth [19]. Recent experimental data [20] provide evidence that invasive cancer cells impact
surrounding adipocytes; peritumoral adipocytes exhibit a modiﬁed phenotype and speciﬁc biological
features sufﬁcient to be named cancer-associated adipocytes; cancer-associated adipocytes modify the
cancer cell characteristics/phenotype leading to a more aggressive behaviour. Adipocytes within a context
of obesity, by the action of “adipokines”, participate in a highly complex cross talk with tumour cells to
promote tumour progression.
Two adipokines, leptin and adiponectin, have been recently studied for their inﬂuence on the breast
cancer risk and tumour biology. Their biological activities as their effects on breast neoplastic cells are
largely in opposition to each other. A third adipokine, the HGF, can have a positive effect on tumour
development as a result of its speciﬁc angiogenic properties and capacity to promote neoplastic invasion.
Among the adipose tissue-derived factors an emerging central role in the breast cancer pathogenesis and
prognosis has been recently attributed to inﬂammatory mediators, that is, proinﬂammatory cytokines TNF-
α and IL-6.
The exact interplay between these different adipokines is yet nor well clariﬁed; therefore, we will
analyse them in detail discussing the most updated and useful ﬁndings in order to better explain their
relationship and role in the pathogenesis of breast cancer.
4.1. Leptin
Among adipokines, leptin plays a central role as irreplaceable prognostic and predictive factor. Leptin
is secreted by adipocytes proportionally to BMI as well as nutritional status and acts mainly upon the
hypothalamus to regulate food intake and energy metabolism [21]. It is also synthesised by preadipocytes,
especially when these are stimulated in a paracrine way by the proinﬂammatory cytokines secreted by the
macrophages inﬁltrating the adipose tissue [22]. Taking into account its numerous endocrine functions,
leptin can be considered the prototype for all the adipose tissue-derived hormones. This has rapidly led
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to hypothesise a correlation between its circulating levels and breast cancer risk. Women with breast
cancer have higher leptin plasma levels and mRNA expression in adipose tissue as compared to healthy
subjects, and the blood levels of estradiol increase concomitantly to those of leptin [23]. Then, a reciprocal
functional dependency between leptin and the ER/ligand system is strongly conceivable. Indeed, estrogens
induced a reversible increase in leptin mRNA expression and secretion from the adipose tissue [24]a n d
high intratumoral levels of leptin in ER+ tumours are speciﬁcally involved in cancer growth stimulation
through an autocrine mechanism [25]. However, Chen et al. [26] demonstrated that tumour surgical excision
did not inﬂuence circulating leptin levels in patients with breast carcinoma. This is consistent with the
idea that the tumour leptin production is only a minor source, whereas the adipose tissue is the main
contributor to its circulating levels. Accordingly, serum leptin levels are not signiﬁcantly different between
premenopausal breast cancer patients and healthy women [27]. This result conﬁrmed that leptin presumably
does not inﬂuence mammary tumorigenesis in peri/premenopause but is a speciﬁc factor of postmenopause
correlated with weight and hyperestrogenism. Indeed, it has been recently demonstrated that serum leptin
levels signiﬁcantly correlate with total body aromatasic activity in postmenopausal breast cancer patients
[28]. Goodwin et al. [29] observed an association also between high plasma leptin concentrations and
negative steroid hormone receptor status. Then, the mechanism through which leptin promotes breast
tumour growth is complex. Recent studies have demonstrated that leptin is able to inﬂuence different
second intracellular messengers involved in breast cancer cell proliferation and survival, such as signal
transducers and activators of transcription 3 (STAT3), transcription activator protein 1 (AP-1), extracellular
signalregulatedkinase-2(ERK2)andMAPK.Thesemechanismsofsignaltransductionseemtobeinvolved
in the regulation of aromatase expression, estrogen synthesis, and ER activation. Furthermore, there is
evidence that leptin can induce the direct activation of ER in MCF-7 breast cancer cells even in the absence
of its natural ligand (E2) as well as upregulate the estradiol/ERα signalling in MCF-7 cells exposed to
aromatizable androgen, and the latter signal is downregulated by the aromatase inhibitors [30]. Furthermore,
leptin interferes with the insulin signalling, and plasma levels of leptin directly correlate with the degree
of insulin resistance in patients with type-2 diabetes [31], whose association with breast carcinoma is well
known. In a recently published paper, we demonstrated that in postmenopausal breast cancer patients, BMI,
leptin, and interleukin-6 were signiﬁcantly correlated with pathological tumour size (pT) and TNM stage.
At multivariate regression analysis, BMI and leptin were independent predictive variables of pT and TNM
stage. These results seem to suggest a twofold role of leptin in the etiopathogenesis of postmenopausal
estrogen-positive breast cancer. Indeed, leptin reﬂects the total amount of fat mass, which correlates to
aromatase activity and subsequent estrogens levels [32].
4.2. Adiponectin
Adiponectin (ApN) acts through its two receptors, AdipoR1 and AdipoR2, which are expressed widely in
various tissues, including breast tissue. Binding of ApN to its receptors activates AMP-activated protein
kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR)-γ metabolic pathways, leading
to an increase in fatty acid oxidation, glucose uptake, and a decreased rate of gluconeogenesis, thus
enhancing insulin sensitivity. The physiologic functions of ApN are mainly endocrine, but it exerts also
paracrine actions, such as the inhibition of the leptin-induced production of macrophage TNF-α [33]. ApN
biosynthesis is inhibited by the increase of fat concentrations in adipocytes, and therefore, its circulating
levels are lower in obese or overweight patients.
Studies conﬁrm a signiﬁcant inverse correlation between serum ApN levels, breast cancer risk,
and poor prognosis, independently from hormone receptor status [34]. ApN inhibits the proliferation of
several cell types and is a negative regulator of angiogenesis [35]. It has been shown that ApN, binding
to its receptors, activates the PPAR-γ pathway, which, in turn, induces the transcription of several genes
involved in the regulation of cell proliferation and differentiation. Previous studies have demonstrated the
importance of PPARs in the pathogenesis of breast cancer [36]. A plausible explanation of the association
between ApN levels and breast carcinoma risk is that the reduction of ApN may result in a decreased
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activation of PPAR signalling and low nuclear levels of BRCA1 with subsequent damage to DNA repair
mechanisms. Therefore, overweight subjects with low serum levels of ApN could also have an increased
risk of developing tumours with an aggressive phenotype and enhanced neoangiogenesis.
4.3. Hepatocyte Growth Factor
The adipocytes and the stromal cells of the adipose tissue seem to be one of the main sources of HGF
synthesis, and therefore, it should be rightfully considered as an adipokine. Serum HGF levels positively
correlate with BMI and decrease following body weight loss [37]. The HGF exerts several functions which
inﬂuence the development and metastatisation of breast cancer. Serum HGF levels have been demonstrated
to signiﬁcantly correlate with high stage, ER-, degree of differentiation, and presence of lymph node and
distant metastases in patients with locally advanced breast cancer [38].
4.4. Tumor Necrosis Factor-α
The TNF-α was the ﬁrst inﬂammatory cytokine to be identiﬁed as a product of adipocytes. Within the
adipose tissue, TNF-α is produced by adipocytes, stromavascular cells, and macrophages, and its expression
is greater in subcutaneous than in visceral adipose tissue. Both in experimental models and in humans,
adipose tissue expression of TNF-α increases with obesity and is positively correlated with the amount of
adipose tissue [39]. The extent to which TNF-α produced by the adipose tissue is secreted in the circulation
is unknown, even though a correlation between TNF-α levels and obesity indices has been reported. TNF-α
in the adipose tissue acts both in an autocrine and paracrine way to inﬂuence a range of processes, including
apoptosis and synthesis of other cytokines and adipokines. Interestingly, TNF-α regulates IL-6 synthesis
and aromatase expression in the adipose tissue, thus stimulating estrogen production [40]. Moreover, it
has been suggested that TNF-α plays a role in the development of insulin-resistance through the inhibition
of the insulin receptor-signalling pathway [41]. Thus, overweight subjects may have increased circulating
TNF-α levels that could promote breast tumorigenesis through the induction of insulin-resistance and IL-6
and estrogens biosynthesis.
4.5. Interleukin-6 (IL-6)
IL-6 is a known inﬂammatory cytokine secreted by activated macrophage and involved in several functions
of the immune response that exerts also various metabolic and endocrine activities. It has been demonstrated
that IL-6 increases following menopause in healthy women [42], also it is released by adipocytes, and, by
acting both locally and in a systemic fashion, it could disrupt the synthesis of estrogens. Both IL-6 plasma
levels and its expression in the adipose tissue are high under obesity and insulin-resistance conditions [43].
Slattery et al. [44] found a signiﬁcant interaction between high waist-to-hip ratio, a speciﬁc IL-6 genotype,
and an increased risk of breast cancer, thus suggesting that IL-6 genotypes may inﬂuence breast cancer
risk in conjunction with central adiposity in postmenopausal women. Moreover, a recent paper showed
that the association between a speciﬁc IL-6 promoter haplotype and worse outcomes in breast cancer
patients was limited to those patients with ER+ tumours, thus providing further support for the hypothesis
that IL-6 exerts its effect on breast cancer cells at least in part through hormonal pathways [45]. In fact,
IL-6 acts as a regulator of estrogen synthesis and aromatase expression and activity both in the adipose
tissue and in malignant breast tissue, contributing to breast cancer progression [46]. A recent in vitro paper
demonstrated that adipocytes isolated from breast tumour samples overexpressed IL-6 and that higher levels
of this cytokine were associated with the tumours of larger size and with lymph-node involvement [20].
Therefore, IL-6 seems to play a key role in the acquired proinvasive feature of tumour cells. Furthermore,
IL-6 induces cell migration through the activation of the MAPK pathway, acts as an antiapoptotic factor,
promotes the osteoclasts formation, and inhibits the differentiation of dendritic cells, thus facilitating the
metastatic process.
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In conclusion, IL-6 may be associated with breast cancer through several mechanisms, including
regulation of insulin, inﬂammation, and estrogen, all factors that may signiﬁcantly inﬂuence the evolution
of this disease [47]. In fact, proinﬂammatory cytokines could facilitate tumour growth and metastasis by
altering tumour cell biology and activating stromal cells, tumour-associated macrophages and ﬁbroblasts
[48]. Moreover, systemic chronic inﬂammation mediated by IL-6 may increase the risk of breast cancer
recurrence and affect its prognosis [49].
5. OXIDATIVE STRESS
Obesity, as a result of metabolic and inﬂammatory changes, is commonly associated with increased
oxidative stress, the latter characterized by high levels of reactive oxygen species (ROS) [50]. These highly
reactive free radicals created by incomplete reduction of oxygen result in molecules of singlet oxygen and
superoxide. Unless these free radicals are neutralized by antioxidant cell protective mechanisms, they can
cause damage to lipids, proteins, and nucleic acids. ROS could also lead to progressive genetic instability,
tumour progression, and metastasis in triggering the P13K/Akt pathway that, in turn, is activated by some
of the obesity-associated cytokines and growth factors and mutagenic changes [51].
Increased oxidative stress in accumulated fat has recently been identiﬁed as an important pathologic
mechanism in insulin resistance and metabolic syndrome. In turn, energy balance changes have marked
effects on ROS levels in obese subjects: dietary energy restriction brings acute reduction in ROS, whereas
overfeeding increases levels of ROS [52]. Accordingly, it has been demonstrated that common single-
nucleotide polymorphisms (SNPs) in candidate genes related to oxidative stress was associated with
postmenopausal breast cancer risk [53].
Indeed, there is evidence that oxidative stress is involved in breast carcinogenesis. Production of ROS
and nitric oxide (NO) species in cancer-associated ﬁbroblasts is sufﬁcient to induce genomic instability in
adjacent cancer cells, via a bystander effect, potentially increasing their aggressive behaviour. Breast cancer
cells use “oxidative stress” in adjacent ﬁbroblasts as an “engine” to fuel their own survival via the stromal
production of nutrients. Therefore, treatment with antioxidants (such as N-acetyl-cysteine, metformin, and
quercetin) or NO inhibitors seems to be sufﬁcient to reverse many of the cancer-associated ﬁbroblast
phenotypes [54].
6. THERAPEUTIC PERSPECTIVES
Antiestrogens, such as tamoxifen, were the ﬁrst drugs developed for the treatment of hormone-dependent
breast cancer. The third-generation aromatase inhibitors have been shown to be superior to tamoxifen
in terms of reducing recurrence risk and are recommended for the treatment of postmenopausal women
with hormone receptor-positive breast cancer, both in the metastatic and adjuvant and neoadjuvant setting.
Importantly, as the reduction in the risk of distant metastases often precedes improvements in overall
survival, these results may translate into a signiﬁcant survival beneﬁt with longer follow-up.
Despite the involvement of estrogens in the aetiology and progression of breast cancer, about 30%
of these tumours do not express the ER, and then, they are refractory to the antiestrogen therapy. Moreover,
about 40% of breast tumours have ER but fail to respond to hormonal therapy. These ﬁndings warrant a
careful assessment of the mechanism through which estrogens carry out their actions and the implication of
possible alternative or synergic mechanisms capable of regulating tumorigenesis and progression of breast
carcinoma.
Recent studies were trying to better understand the potential inﬂuence of each adipokine on the
tumorigenesis of breast cancer. In fact, a better understanding of each adipokine function may be extremely
important to enable the further identiﬁcation of key molecules involved in the development of breast
carcinoma and to suggest new therapeutic options.
The identiﬁcation of leptin and the demonstration that its circulating concentrations positively
correlate with BMI have been followed by attempts to link serum leptin levels to breast cancer risk. To
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date, however, these studies have reported conﬂicting results. This is mainly because leptin was assessed
indiscriminately and not in speciﬁc populations of postmenopausal rather than premenopausal patients or in
patients with ER+ rather than ER− tumors. Indeed, it should be pointed out that the link between leptin and
breast cancer goes through the well-known correlation of postmenopause and subsequent body weight gain,
with the increase of aromatase activity and leptin levels also resulting from increased fat mass. Moreover,
it is important to underline that leptin seems to have direct and speciﬁc actions on the neoplastic cell.
Therefore, the role of leptin in the etiopathogenesis of breast cancer and its development would thus seem
to be twofold: (1) direct and (2) indirect. In the ﬁrst instance, leptin performs as a growth factor regardless
of hormonal status and acts directly on its receptor present in the neoplastic cells. In the second instance,
leptin levels reﬂect the total amount of fat mass, which can be directly correlated to the aromatasic activity
and the subsequent amount of estrogens [1].
These observations are of course meaningful only for that speciﬁc subgroup of patients, where
increase of adipose tissue, hormone dependency, oncogenesis, tumour growth, and progression are strictly
correlated. In this scenario, the direct proneoplastic action of leptin is associated to aromatase hyperactivity.
In this respect, great importance would be assigned to the use of aromatase inhibitors in the function of
the BMI and the subsequent levels of leptin. Paradoxically, in obese women, we could be faced with an
optimum action of the aromatase inhibitors in their capacity to suppress estrogen synthesis, but such effect
could be in part counteracted by permanent high leptin levels capable of independently perform a speciﬁc
stimulus of the neoplastic proliferation.
In the light of these considerations, antiestrogen and aromatase inhibitors therapy may have a
different effectiveness for postmenopausal women with breast carcinoma in respect of BMI and leptin
levels. A recently published exploratory analysis from the ATAC trial [55] showed that postmenopausal
ER-positive breast cancer patients with a high BMI (BMI > 35kg/m2) at baseline had a signiﬁcantly
higher rate of breast cancer recurrence compared to those women with a low BMI (BMI < 23kg/m2)
and signiﬁcantly more distant recurrences. In detail, recurrence rates in the anastrozole group were
lower than those in the tamoxifen group at all BMI levels although the beneﬁt of anastrozole was
greater in thinner women (BMI > 30kg/m2 versus BMI < 28kg/m2). One possible explanation for
these ﬁndings is (as authors stated in the paper) that higher estrogen levels resulting from a high
BMI may lead to incomplete inhibition with anastrozole. It seems that there are overweight/obese
women whose extraglandular aromatisation from adipose tissue cannot be fully suppressed by the
standard treatment dose of 1mg/day of anastrozole. Therefore, women with a high BMI might need
higher dosages to achieve the fully antitumor efﬁcacy of this drug. To test this hypothesis, a thorough
assessment of BMI-related efﬁcacy of aromatase inhibitors in randomised trials in both adjuvant and
metastatic setting is warranted. Therefore, the evaluation in properly designed and adequately powered
clinical trials of the potential beneﬁt of adjusting dose of aromatase inhibitors by body weight will
be critical in determining whether outcomes for overweight and obese breast cancer patients can be
improved.
Moreover, as discussed in the present paper, other obesity-associated factors, including insulin,
adipokines (i.e., leptin), and inﬂammatory mediators, may inﬂuence breast cancer growth and prognosis
independently of estrogens and at least in part by interacting with estrogen signalling at a cellular level. In
particular, leptin competes with antiestrogens for the modulation of ER activity, and thus, high serum levels
of leptin in overweight breast cancer patients might contrast the inhibitory effects of antiestrogenic therapy
on cell proliferation and ER expression and transcription. Leptin, with its capacity to increase the activation
of estrogen receptors, may reduce or even overcome the antiproliferative effects induced by antiestrogen
in breast carcinoma cells [56]. In summary, the mass of evidence available so far seems to suggest that
the increased leptin synthesis in postmenopausal overweight women may promote breast cancer growth by
directly interacting with its speciﬁc receptor and by indirectly acting on the signalling pathways related to
ER. Therefore, it is important to assess the use of drugs which act on the several altered pathways correlated
to obesity.
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6.1. Antidiabetic Drugs: Metformin
DrugssuchasoralhypoglycaemicagentsaswellasthosewhichactonIGF-IRcouldbeeffectiveinreducing
the insulin-mediated tumour cells growth. In the same way the adiponectin receptor agonists could offer a
new therapeutic approach to improve insulin-resistance and directly inhibit the proliferation of epithelial
breast cells.
The concurrence of clinical and epidemiologic evidence linking hyperinsulinemia, insulin resistance,
and diabetes to poor breast cancer outcomes has been recently coupled with enhanced understanding of
molecular effects of metformin and its potential role in malignancy [57]. It is well known that insulin can
promote tumorigenesis both by a direct effect on epithelial tissues or indirectly affecting the levels of other
modulators, such as IGFs, sex hormones, and adipokines. The insulin/IGF-I signalling pathway is activated
when nutrients are available; vice versa, another alternative way is activated when cells are starved of energy
through the AMPK pathway as a sensor of cellular energy balance [58]. Therefore, AMPK is the central
cellular energy sensor which responds to increases in the adenosine monophosphate/adenosine triphosphate
ratio. Physiological conditions of nutrient deprivation activate AMPK, leading to inhibition of energy-
consuming processes (gluconeogenesis, protein and fatty acid synthesis, and cholesterol biosynthesis)
and the stimulation of processes that generate energy (glycolysis and fatty acid beta oxidation), resulting
in restoration of the adenosine triphosphate supply [59]. One of the major growth regulatory pathways
controlled by AMPK is the mammalian target of rapamycin (mTOR) pathway and its downstream
substrates,suchastheribosomalS6kinase(S6K1).Thispathwayregulatesproteintranslationofcellgrowth
regulators such as cyclin D, hypoxia-inducible factor 1α (HIF1α), and MYC. All these factors control key
cell processes such as cycle progression, growth, and angiogenesis [60].
Consequently, IGF signalling concurs to normal cell growth, but it is also a known mediator of
the malignant phenotype. IGF-I receptor ligand binding leads to autophosphorylation of tyrosines at its
kinase domain; this induces the phosphorylation of tyrosines and serines to form binding sites for insulin
receptor substrates (IRSs) and Src and subsequent activation of signalling via the phosphatidylinositol-3-
kinase(PI3K)/Akt/mTORandRAS/RAF/mitogen-activatedproteinkinase(MAPK)pathways.Itisrelevant
that mTOR activity is in part regulated by cellular energy levels and nutrients as well as oxygen and growth
factors. When mTOR is deregulated, it leads to increased cell growth and proliferation. Therefore, on
the basis of the above reports, insulin, both directly and indirectly, promotes lipid, protein, and glycogen
synthesis, whereas AMPK inhibits these biosynthetic pathways [60].
Exciting preclinical studies have demonstrated that the antidiabetic drug metformin can inhibit the
growth of cancer, including breast cancer cells [61]. Also, population studies increasingly suggest that
metformin decreases the incidence of cancer and cancer-related mortality in diabetic patients [62, 63]. More
recently, a retrospective study in breast cancer patients who received neoadjuvant chemotherapy showed
that diabetic patients receiving metformin during their neoadjuvant chemotherapy had a higher pathological
complete response rate than diabetic patients not receiving metformin (24% versus 8%, P = 0.007) [64].
The primary actions of metformin are the inhibition of hepatic glucose production and the reduction of
insulin resistance in peripheral tissue leading to enhanced glucose uptake and utilisation in skeletal muscle.
This reduces the levels of circulating glucose and decreases the plasma insulin levels improving long-term
glycemic control and reducing the incidence of diabetes-related complications. The antineoplastic effects of
metformin, in particular in breast cancer,are supported by a speciﬁc biological rationale involving important
factors associated with breast cancer growth and prognosis.
At cell-signalling level, several mechanisms of metformin action have been proposed; the most
important relates to the activation of AMPK [65]. In patients with type 2 diabetes mellitus, the activation of
AMPK by metformin results in partial reversal of metabolic disturbances such as hyperglycaemia, hyper-
insulinemia, and insulin resistance and their mitogenic effects. Therefore, metformin inhibits the growth
of various types of cancer cells both in vitro and in vivo [61] through the activation of AMPK. Activation
of AMPK by metformin results in phosphorylation and stabilisation of tuberous sclerosis complex, which
integrates regulatory inputs including oxygen-dependent signals and growth factor-dependent signalling
pathways such as the PI3K and the MAPK. Activation of AMPK by metformin can phosphorylate and
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activate the tumour suppressor p53 leading to the inhibition of cell division and the induction of apoptosis
in cells that encounter low nutrient conditions [66]. This mechanism can lead to apoptosis in p53-proﬁcient
cells and induce re-expression of functional p53 in cells with low levels of wild-type p53 [67]. However, p53
expression in adipose tissue is involved in the development of insulin resistance, and therefore, metformin-
induced p53 expression may be expected to increase insulin resistance [68].
However, the majority of the growth inhibitory effects of metformin are mediated through the
inhibition of mTOR signalling: mTOR phosphorylates downstream mediators leading to the regulation
of cell-cycle progression, cell growth, and angiogenesis. Also, metformin-induced reduction of HER-2
protein expression in human breast cancer cells is mediated by inhibition of mTOR [69]. Other reported
mechanismsofactionformetformin includereducedinsulin-like growthfactor,insulin-mediatedsignalling,
theinhibition ofangiogenesis,andtheinductionofcell-cyclearrestandapoptosis.Metformin mayalsohave
antiproliferative effects both by reversing hyperinsulinaemia and also by indirectly lowering IGF-I levels
through effects on insulin and insulin-binding proteins levels [70].
The inhibition of angiogenesis is another proposed mechanism of metformin’s effect. Metformin
attenuates angiogenic stimuli in the serum of polycystic ovarian syndrome patients with insulin resistance
and decreases levels of vascular endothelial growth factor (VEGF) in obese diabetic patients. In addition, in
vitro studies have shown the inhibition of angiogenesis and inﬂammation by metformin through inhibition
of mediators such as HIF-1α, tumour necrosis factor alpha, plasminogen activator inhibitor-1 antigen, and
von Willerbrand factor, possibly through the inhibition of mTOR signalling. Therefore, there is a strong
preclinical rationale for a potentially beneﬁcial effect of metformin in breast cancer outcomes [71].
6.2. Anti-Inﬂammatory Drugs
Since inﬂammation-signalling pathways, through the action of some mediators such as IL-6 and TNF-α,
may inﬂuence breast tumour growth and disease outcome, several studies have investigated associations
between aspirin and nonsteroidal anti-inﬂammatory drugs and breast cancer risk [72]. A recent study
demonstrated that aspirin had the greatest reduction in risk in the presence of a high-risk IL-6 genotype
and a more modest effect in the presence of the lower-risk allele and concluded that the joint effect of
IL-6 genotype and aspirin use attenuated the expected risk in a multiplicative way among postmenopausal
women [73].
Aspirin and other NSAIDs are widely used for the treatment of minor injuries and headaches,
degenerative joint diseases such as rheumatoid arthritis, and as prophylaxis against cardiovascular diseases.
NSAIDs inhibit the activity of COX leading to the inhibition of synthesis of prostaglandins (PGs) that cause
inﬂammation, swelling, pain, and fever. Some NSAIDs are more potent against COX-1 (e.g., aspirin); others
have greater afﬁnity for COX-2.
Increasing evidence from in vitro and animal models as well as human epidemiological studies
suggests that aspirin and other NSAIDs may prevent the occurrence of cancers of epithelial origin [74].
In particular, daily intake of NSAIDs, primarily aspirin, produced risk reductions of 39% for breast cancer
[75]: these chemopreventive effects were apparent after 5 or more years of NSAID use and were stronger
with longer duration. These observations have collectively initiated a wide variety of investigations to
determine the mechanisms by which aspirin and other NSAIDs reduce the risk or progression of cancers.
In detail, research on human cell lines and animal models indicates a role for COX-2 in breast
carcinogenesis, thus suggesting that selective COX-2 (sCOX-2) inhibitors and NSAIDs may prevent the
growth of mammary tumours. In fact, COX-2 is overexpressed in approximately 40% of human breast
tumours, and it is induced in response to stimuli such as cytokines [76].
NSAIDs may exert a protective effect against breast cancer, apart from by inhibiting COX-2, by
reducing the level of prostaglandins, estrogens, and/or prolactin [77, 78]. Furthermore, studies in the
literature suggest that in different cancer cells, aspirin induces the upregulation of their mitochondrial
proapoptotic proteins, such as Bax and Bak, and the downregulation of antiapoptotic proteins such as Bcl-2
and Bcl-xl [79] as well as increases mitochondrial membrane permeability and the release of cytochrome c,
leading to the activation of caspases and cell apoptosis [80]. One of the most widely accepted mechanisms
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for the anticancer effect of NSAIDs is the reduced PG synthesis through acetylation and inhibition of COX.
However, NSAIDs have growth inhibitory effects also against cancer cell lines that do not express COX-1
or -2 and against mouse embryo ﬁbroblasts that are null for both enzymes [81]. These observations suggest
that COX-independent pathways may also contribute to the anticancer effects of NSAIDs. Although the
effects of aspirin on COX have been well studied, little is known as to whether it induces acetylation of
cellular proteins, particularly those that regulate apoptosis, which may also contribute to its anticancer
effects. Alfonso et al. demonstrated that the ability of aspirin to induce apoptosis involves acetylation of
the tumour suppressor protein p53 [82], leading to the modulation of its target genes, p21CIP1, a protein
involved in cell cycle arrest, and Bax, a mitochondrial pro-apoptotic protein.
Another possible mechanism by which the COX/PGE2 cascade promotes breast cancer is via
increasing estrogen production. It is known that PGE2 upregulates aromatase activity leading to increased
estrogen synthesis, and recently, vice versa dose-dependent decreases of aromatase activity were observed
in breast cancer cells following treatment with NSAIDs, a COX-1 selective inhibitor, and COX-2 selective
inhibitors [83]. Indeed, laboratory results have shown that estradiol production is decreased in breast
cells exposed to the selective COX-2 inhibitor celecoxib [84]. Although the above-mentioned pathway
through which NSAIDs may decrease the development of breast cancer has been previously highlighted,
the association between NSAID use and circulating estradiol in women is currently unknown. Therefore,
a recent cross-sectional investigation demonstrated that NSAID use was associated with lower circulating
estradiol levels in a population of postmenopausal women not taking menopausal hormone therapy [85],
thussuggestingapotentialmechanismthroughwhichNSAIDsexerttheirprotectiveeffectsonbreastcancer.
To date, however, results of epidemiological studies of NSAIDs and breast cancer risk have been
uncertain. In fact, some cohort studies [86, 87] have found a reduced risk of breast cancer associated
with aspirin use. On the other hand, others [88, 89]h a v ef a i l e dt oﬁnd any association or have even
suggested an increased risk. Few meta-analyses of this association have been performed, and all have
methodological limitations. None was exhaustive, and none assessed heterogeneity in an in-depth manner.
However, recently, an exhaustive meta-analysis on NSAID use and risk of breast cancer was carried out
following the MOOSE guidelines for meta-analyses of observational studies and provided evidence that
NSAID use is associated with reduced risk for breast cancer. The authors included COX-2-nonselective
inhibitors (a group that contains aspirin and ibuprofen as the most widely used drugs) as well as the more
recent COX-2-selective inhibitors with the aim to provide a more deﬁnitive answer about a possible inverse
correlation between the use of these drugs and the risk for breast cancer [90].
7. CONCLUSIONS
The evidence currently available in the literature would seem to suggest that the expression of adipokines as
well as that of estrogens differ according to BMI changes and energy metabolic status. Therefore, a careful
assessment of the nutritional status and body composition is paramount for a proper therapeutic approach
for postmenopausal breast carcinoma. The use of antidiabetic and anti-inﬂammatory drugs associated with
conventional hormone therapies and dietary/physical interventions could offer a new therapeutic approach
for breast carcinoma that develops in the context of adiposity (Figure 2).
Different dietary patterns were demonstrated to inﬂuence breast cancer risk [91]: in particular, a
food pattern characterized by high-fat food choices was signiﬁcantly associated with increased risk of
breast cancer. Moreover, data from epidemiological studies suggest that physical activity is important in
reducing the risk of breast cancer in postmenopausal women [73]. Indeed, these approaches target the
upstream factors, that is, adiposity and physical inactivity, which drive chronic inﬂammation linked to breast
carcinogenesis and prognosis.
To date, however, only few randomized clinical trials have investigated the associations of diet,
physical activity, or weight with prognosis among women diagnosed with breast cancer [92]. An analysis
of lifestyle and survival in the control arm of the Women’s Healthy Eating and Living Study (WHEL)
trial found that the combination of consuming ﬁve or more daily servings of vegetables and fruits and


























FIGURE 2: Potential therapeutic approaches for postmenopausal hormone-dependent breast carcinoma
which develops in the context of adiposity. Adipokines-, insulin-, inﬂammation-, and angiogenesis-signalling
pathways inﬂuence the development of hormone-dependent breast carcinoma and might represent new
targets of treatment in combination with conventional hormone therapies. COX-2, cyclooxygenase-2; E,
estradiol; HGF, hepatocyte growth factor; IGF, insulin growth factor; IL, interleukin; TNF, tumour necrosis
factor; VEGF, vascular endothelial growth factor.
accumulating ≥540 metabolic equivalent tasks-minutes/wk (equivalent to walking 30 minutes 6days/wk),
was associated with a signiﬁcant survival advantage (HR, 0.56; 95% CI, 0.31 to 0.98). These ﬁndings were
similar in obese and nonobese women and were stronger in those with estrogen receptor-positive tumours.
Behaviour changes associated with increased physical activity have also been shown to moderately decrease
cancer incidence, slow down cancer progression in model systems, and improve cancer survival by multiple
mechanisms, including improved insulin resistance resulting in lower insulin levels, reduced circulating
bioactive hormone concentrations resulting in increased steroid hormone binding proteins, and reduced
inﬂammatory cytokines. Recent publications have reported on associations between physical activity and
prognosis among breast cancer survivors. In 2,987 women from the Nurses’ Health Study diagnosed with
stage I to III breast cancer between 1984 and 1998 and followed until death or 2002, the relative risk of
death from breast cancer for activity equivalents of walking was 0.80 for 1 to 3hours/wk, 0.50 for 3 to
5hours/wk, 0.56 for 5 to 8hours/wk, and 0.60 for ≥8hours/wk, compared with inactive women. In a cohort
of 688 women diagnosed with local or regional breast cancer between 1995 and 1998 and observed until
death or 2004, the HR for total deaths for women expending the energy equivalent of 2 to 3hours/wk of
brisk walking at 2 years after diagnosis was 0.33 (95% CI, 0.15 to 0.73, P for trend 0.046) compared with
inactive women. In a cohort of 1,970 early-stage patients with breast cancer identiﬁed primarily through a
health maintenance organization, a protective association between physical activity and all-cause mortality
remained in multivariable analyses (HR, 0.66; 95% CI, 0.42 to 1.03; P for trend = 0.04).
Future studies that exploit emerging ways to target energy balance-responsive pathways through
combinations of lifestyle (particularly diet and physical activity) and pharmacologic approaches will
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facilitate the translation of this research into effective cancer prevention and targeted effective therapeutic
strategies in humans.
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